
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydromorphone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravenous Hydromorphone for the Treatment of Acute Pain
Details : Hydromorphone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Chest Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2025
Lead Product(s) : Hydromorphone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nalbuphine HCl is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Insufficiency.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase II
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase II
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2023
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Wuhan Union Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Rematazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Emergence Delirium.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients
Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Analgesia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Remimazolam Besylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : The First Affiliated Hospital of Zhengzhou University
Deal Size : Inapplicable
Deal Type : Inapplicable
the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation
Details : Remifentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Critical Illness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2015
Lead Product(s) : Remifentanil
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : The First Affiliated Hospital of Zhengzhou University
Deal Size : Inapplicable
Deal Type : Inapplicable
